Intelligence Feed event · Policy · 2026-09-13

    Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit

    Question

    Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit

    Direct answer

    Liquidia has scaled its inhaled treprostinil formulation Yutrepia to more than 5,000 patients as of July 2026. Commercial adoption is progressing in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. However, continued patent infringement challenges from incumbent United Therapeutics, combined with elevated R&D spending, have pressured LQDA valuation multiples.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-13
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit”, revision 1, evidence through 2026-09-13. https://marketontology.com/market-events/2026-09-13/liquidia-surpasses-5-000-yutrepia-patients-amid-united-therapeutics-patent-suit-83cb3e

    POLICY
    Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit
    Liquidia has scaled its inhaled treprostinil formulation Yutrepia to more than 5,000 patients as of July 2026. Commercial adoption is progressing in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. However, continued patent infringement challenges from incumbent United Therapeutics, combined with elevated R&D spending, have pressured LQDA valuation multiples.
    LQDAUTHR
    Impact
    59
    SEP 13
    SIG
    81%
    LQDAUTHR
    Liquidia Surpasses 5,000 Yutrepia Patients Amid United Therapeutics Patent Suit
    Liquidia has scaled its inhaled treprostinil formulation Yutrepia to more than 5,000 patients as of July 2026. Commercial adoption is progressing in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. However, continued patent infringement challenges from incumbent United Therapeutics, combined with elevated R&D spending, have pressured LQDA valuation multiples.
    → Accelerated Yutrepia patient conversion compresses UTHR Tyvaso market share in pulmonary hypertension while ongoing litigation elevates LQDA legal cost burden.
    Impact
    Liquidia has scaled its inhaled treprostinil formulation Yutrepia to more than 5,000 patients as of July 2026. Commercial adoption is progressing in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. However, continued patent infringement challenges from incumbent United Therapeutics, combined with elevated R&D spending, have pressured LQDA valuation multiples.
    Affected
    LQDAUTHR
    Transmission
    Accelerated Yutrepia patient conversion compresses UTHR Tyvaso market share in pulmonary hypertension while ongoing litigation elevates LQDA legal cost burden.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    LQDAcommercial revenue ramp offset by litigation expense dragMixed1-4wYutrepia reaches 5,000 patients as LQDA manages active United Therapeutics patent litigation
    UTHRmarket share erosion in inhaled prostacyclin therapiesDown1-3mCompetitor Yutrepia scaled to 5,000 patients in shared therapeutic category

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month